Simulations Plus (SLP) Stock Price, News & Analysis

Company Overview

Simulations Plus, Inc. develops software and provides consulting services for pharmaceutical and biotechnology companies involved in drug discovery and development. Its modeling and simulation tools are designed to help researchers evaluate drug candidates, understand how medicines move through the body, assess safety risks and support decisions throughout the development process.

The company’s products include GastroPlus, a platform used for physiologically based pharmacokinetic and biopharmaceutic modeling; ADMET Predictor, which helps predict absorption, distribution, metabolism, excretion and toxicity characteristics; and DILIsym, a software platform focused on drug-induced liver injury. Simulations Plus also offers additional modeling tools and scientific services covering pharmacokinetics, pharmacodynamics, toxicology and related areas.

Founded in 1996, Simulations Plus serves pharmaceutical and biotechnology companies, contract research organizations, regulatory agencies and academic institutions. Its customer base is international, reflecting the company’s role in supporting drug research and development across major global pharmaceutical markets.

Key Stats

• Today's Range: $18.41 to $18.45
• 50-Day Range: $18.21 to $18.44
• 52-Week Range: $11.09 to $21.01
• Volume: 232,124 shs
• Average Volume: 162,488 shs
• Market Capitalization: $372.43 million
• P/E Ratio: 46.03
• Dividend Yield: N/A
• Price Target: $17.25
• Consensus Rating: Reduce

Simulations Plus Stock Analysis - MarketRank™

Simulations Plus scored higher than 12% of companies evaluated by MarketBeat, and ranked 852nd out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Simulations Plus has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.

Downside Risk

Simulations Plus has a consensus price target of $17.25, representing about 6.3% downside from its current price of $18.41.

Amount of Analyst Coverage

Simulations Plus has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Simulations Plus is 46.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of Simulations Plus is 46.03, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.29.

Price to Book Value per Share Ratio

Simulations Plus has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.34% of the float of Simulations Plus has been sold short.

Short Interest Ratio / Days to Cover

Simulations Plus has a short interest ratio ("days to cover") of 17.79, which indicates bearish sentiment.

Change versus previous month

Short interest in Simulations Plus has recently increased by 0.65%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Simulations Plus does not currently pay a dividend.

Dividend Growth

Simulations Plus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.42

News Sentiment

Simulations Plus has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Simulations Plus this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for SLP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Simulations Plus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Simulations Plus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $95,384.00 in company stock.

Percentage Held by Insiders

19.10% of the stock of Simulations Plus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.08% of the stock of Simulations Plus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/09/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 8/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:SLP
• CIK: 1023459
• Web: www.simulations-plus.com
• Phone: (661) 723-7723
• Fax: 661-723-5524
• Employees: 213
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Simulations Plus: $17.25
• High Price Target: $18.50
• Low Price Target: $16.00
• Potential Upside/Downside: -6.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.40
• Trailing P/E Ratio: 46.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.72 million
• Net Margins: 9.88%
• Pretax Margin: 15.30%
• Return on Equity: 13.50%
• Return on Assets: 12.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: $79.18 million
• Price / Sales: 4.70
• Cash Flow: $1.43 per share
• Price / Cash Flow: 12.88
• Book Value: $6.20 per share
• Price / Book: 2.97

Miscellaneous

• Outstanding Shares: 20,230,000
• Free Float: 16,362,000
• Market Cap: $372.43 million
• Optionable: Optionable
• Beta: 1.33